Trials / Completed
CompletedNCT04542980
Qualitative Evaluation of Tear Fluid and Blood for Auto Antibodies Produced in Response to COVID-19
Qualitative Evaluation of Tear Fluid and Blood for IgM and IgG Produced in Response to SARS-CoV2, the Virus Responsible for COVID-19.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 44 (actual)
- Sponsor
- Namida Lab · Industry
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This study objective is to collect tear and blood samples from individuals with positive SARS-COV2 diagnosis and test those samples for the presence of various SARS-COV2 viral antigens and autoantibodies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | SARS-CoV2 Autoantibody detection | Through the data collected from this study we hope to support the development of an ELISA assay for the detection of IgM and IgG autoantibodies produced in response to the presence of SARS-CoV2 |
Timeline
- Start date
- 2020-09-15
- Primary completion
- 2020-12-31
- Completion
- 2020-12-31
- First posted
- 2020-09-09
- Last updated
- 2022-03-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04542980. Inclusion in this directory is not an endorsement.